{"id":"dpp-4-inhibitor-metformin-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbance (nausea, diarrhea)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Lactic acidosis (rare, metformin-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DPP-4 inhibitors prolong the action of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion in response to elevated blood glucose. Metformin decreases hepatic gluconeogenesis and improves insulin sensitivity in peripheral tissues. The combination provides complementary mechanisms to lower fasting and postprandial glucose levels.","oneSentence":"This combination inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels while metformin reduces hepatic glucose production, together improving glycemic control in type 2 diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:45:01.720Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT07374328","phase":"PHASE1, PHASE2","title":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-06-01","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT07241897","phase":"PHASE3","title":"DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-12-15","conditions":"Ischemic Stroke, Diabete Mellitus","enrollment":312},{"nctId":"NCT03464045","phase":"","title":"Empa PASS on Urinary Tract Malignancies","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-11-16","conditions":"Diabetes Mellitus, Type 2","enrollment":344995},{"nctId":"NCT03717194","phase":"PHASE3","title":"Effect of Ertugliflozin on Cardiac Function in Diabetes","status":"COMPLETED","sponsor":"Soo Lim","startDate":"2019-06-01","conditions":"Type2 Diabetes, Heart Failure","enrollment":102},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT06145360","phase":"PHASE4","title":"Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient","status":"COMPLETED","sponsor":"SINA Health Education and Welfare Trust","startDate":"2023-12-01","conditions":"Glucose Metabolism Disorders, Diabetes Mellitus, Type 2, Hypoglycemic Agents","enrollment":150},{"nctId":"NCT06218342","phase":"PHASE4","title":"Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-02-15","conditions":"Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease","enrollment":156},{"nctId":"NCT06164535","phase":"PHASE4","title":"The Effects of DPPIs on Cognitive Function of Diabetic Patients","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2023-12-30","conditions":"Cognitive Impairment","enrollment":105},{"nctId":"NCT05977465","phase":"PHASE1, PHASE2","title":"Empagliflozin in Treatment of Peripheral Diabetic Neuropathy","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-01-20","conditions":"Diabetic Neuropathy Peripheral","enrollment":50},{"nctId":"NCT03921242","phase":"","title":"Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2019-08-01","conditions":"Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic","enrollment":4888},{"nctId":"NCT06010992","phase":"PHASE2","title":"Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-10-01","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT03877406","phase":"PHASE4","title":"Effect of Empagliflozin on Body Composition and Ketones","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-08-01","conditions":"Diabetes Mellitus, Fat; Intolerance, Pancreas","enrollment":200},{"nctId":"NCT05902468","phase":"PHASE2, PHASE3","title":"Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-06-28","conditions":"Diabetes Mellitus, Type 2","enrollment":88},{"nctId":"NCT04419337","phase":"PHASE2","title":"Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Stroke","enrollment":200},{"nctId":"NCT03871621","phase":"PHASE4","title":"Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2019-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT05663736","phase":"PHASE4","title":"Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2020-01-01","conditions":"Ejection Fraction","enrollment":80},{"nctId":"NCT05429554","phase":"","title":"The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"MTI University","startDate":"2022-06","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT05386186","phase":"PHASE4","title":"The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes","enrollment":192},{"nctId":"NCT05359341","phase":"NA","title":"Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2020-09-20","conditions":"Diabete Type 2","enrollment":175},{"nctId":"NCT03770052","phase":"PHASE4","title":"Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie","status":"COMPLETED","sponsor":"Pusan National University Hospital","startDate":"2018-10-24","conditions":"Type 2 Diabetes Mellitus, Inadequate Glucose Control","enrollment":159},{"nctId":"NCT02338921","phase":"PHASE4","title":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT03351478","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-11-27","conditions":"Type 2 Diabetes Mellitus","enrollment":770},{"nctId":"NCT04013581","phase":"PHASE4","title":"Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2019-08-05","conditions":"Type 2 Diabetes Mellitus","enrollment":121},{"nctId":"NCT04326166","phase":"","title":"Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.","status":"UNKNOWN","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-03-25","conditions":"Diabetes Mellitus, Type 2","enrollment":1971},{"nctId":"NCT04667143","phase":"PHASE3","title":"Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-01","conditions":"Diabetes Mellitus, Type II","enrollment":760},{"nctId":"NCT02043054","phase":"PHASE3","title":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":90},{"nctId":"NCT02686476","phase":"NA","title":"Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2016-03","conditions":"Non Alcoholic Fatty Liver Disease","enrollment":100},{"nctId":"NCT02231021","phase":"PHASE4","title":"The Practical Evidence of Antidiabetic Combination Therapy in Korea","status":"COMPLETED","sponsor":"Kun-Ho Yoon","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":216},{"nctId":"NCT01009580","phase":"PHASE3","title":"Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":447},{"nctId":"NCT02009488","phase":"PHASE1","title":"Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09-08","conditions":"Diabetes Mellitus, Type 2","enrollment":59},{"nctId":"NCT03249506","phase":"","title":"Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-12","conditions":"Diabetes Mellitus, Type 2","enrollment":25358},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT02798172","phase":"NA","title":"The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy","status":"COMPLETED","sponsor":"Fourth People's Hospital of Shenyang","startDate":"2014-05","conditions":"Diabetes Mellitus, Type 2","enrollment":81},{"nctId":"NCT02106104","phase":"PHASE4","title":"Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-03","conditions":"Type 2 Diabetes","enrollment":48},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02607410","phase":"PHASE4","title":"Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2010-01","conditions":"Type 2 Diabetes Mellitus","enrollment":40},{"nctId":"NCT01805830","phase":"PHASE3","title":"Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2012-05","conditions":"Type 2 Diabetes","enrollment":189},{"nctId":"NCT00964184","phase":"PHASE4","title":"Phenotypic and Genetic Correlates of Diabetes (Non-Type 1) in Young Non-Obese Asian Indians in North India and A Study to Evaluate the Efficacy of Sitagliptin (DPP-4 Inhibitor) in a Sub-group of the Study Population","status":"COMPLETED","sponsor":"Diabetes Foundation, India","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT01106651","phase":"PHASE3","title":"A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2","enrollment":716},{"nctId":"NCT01767389","phase":"","title":"Glucagon-like Peptide (GLP) Utilization and Safety","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1},{"nctId":"NCT01368081","phase":"PHASE3","title":"Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1162},{"nctId":"NCT00984867","phase":"PHASE3","title":"Dapagliflozin DPPIV Inhibitor add-on Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Type 2 Diabetes","enrollment":833},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT01106677","phase":"PHASE3","title":"The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1284},{"nctId":"NCT00575588","phase":"PHASE3","title":"52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-12","conditions":"Type 2 Diabetes","enrollment":891},{"nctId":"NCT00661362","phase":"PHASE3","title":"Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Type 2 Diabetes","enrollment":570}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"DPP-4 inhibitor + metformin group","genericName":"DPP-4 inhibitor + metformin group","companyName":"Beni-Suef University","companyId":"beni-suef-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels while metformin reduces hepatic glucose production, together improving glycemic control in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}